Re: Farmas USA
dejo un articulo de acadia al final deja unas respuestas sin resolver que pudieran ser las causas de que reculara la accion
https://finance.yahoo.com/news/why-acadia-pharmaceuticals-soaring-today-143700265.html?guccounter=1
Now what
2018 has been a rough year for Acadia's shareholders, so it's nice to see some positive news come from the company for a change. Offering healthcare providers new dosing options could help to spur additional usage of the drug and help Nuplazid reach blockbuster status.
However, the big question for Acadia's investors moving forward is how the FDA will respond the to reports of safety issues related to the use of Nuplazid. That question remains unanswered, so I continue to believe caution is warranted
ACAD